Welcome to our dedicated page for LENSAR news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on LENSAR stock.
LENSAR, Inc. (LNSR) is at the forefront of next-generation femtosecond laser technology, specializing in refractive cataract surgery. The company's flagship product, the LENSAR Laser System, offers unmatched precision and accuracy, optimizing visual outcomes for cataract patients. This cutting-edge system features the proprietary Augmented Reality™, LENSAR’s advanced 3-D imaging, measurement, and guidance technology. By providing high-resolution ocular images in a single scan, the system ensures precise surgical incisions and treatments, all within a single procedure room.
Unlike other femtosecond cataract lasers, the LENSAR Laser System is specifically built for refractive cataract surgery. Designed from the ground up with the needs of cataract surgeons in mind, the system integrates a suite of proprietary technologies aimed at improving visual outcomes, efficiency, and reproducibility. These technologies include Streamline IV and IntelliAxis, which assist surgeons with imaging, procedure planning, and precision.
At its core, LENSAR, Inc. is a commercial-stage medical device company committed to revolutionizing refractive eye surgery. Their product portfolio extends beyond the laser system to include the associated consumable components, such as the disposable patient interface device (PID) kits and procedure licenses necessary for each surgical procedure.
LENSAR's focus on innovation doesn't stop at technology. They are dedicated to building a vibrant team of talented and motivated individuals who share their passion for making a significant impact on patients' lives. The company continues to push the boundaries of what's possible in refractive cataract surgery, ensuring that their technology remains at the cutting edge of medical advancements.
LENSAR, Inc. (LNSR) reported financial results for Q1 2021, with total revenues reaching $7.0 million, a 19.3% increase from $5.9 million in Q1 2020. This growth is attributed to enhanced sales of LENSAR Laser Systems and procedure licenses, particularly in the U.S. However, the net loss widened to $5.2 million ($0.56 per share) compared to $3.7 million in the previous year. The company anticipates launching its next-generation system, ALLY™, with a 510(k) filing expected in 2022. As of March 31, 2021, LENSAR held $35.9 million in cash, down from $40.6 million at the end of 2020.
LENSAR, Inc. (NASDAQ: LNSR) will release its first quarter 2021 financial results on May 5, 2021, prior to market opening. The company specializes in advanced femtosecond laser surgical solutions for cataracts and will host a conference call at 8:30 am ET on the same day to discuss these results and recent corporate highlights. Interested participants can join via telephone or access the live webcast on LENSAR's website. The company is committed to enhancing visual outcomes with its proprietary LENSAR Laser System.
LENSAR, Inc. (LNSR) reported fourth quarter 2020 revenue of $8.3 million, a slight decline of 2.1% from $8.5 million in Q4 2019, primarily due to COVID-19 impacts. Yearly revenue fell 13.6% to $26.4 million. Selling, general, and administrative expenses rose 77.8% to $8.7 million in Q4, largely due to stock-based compensation. The net loss for Q4 was $6.8 million, increasing from $2.5 million a year prior. Despite challenges, LENSAR increased its laser system base by 10% and plans to submit a 510(k) application for its ALLY system by Q1 2022, aiming for a launch later in the year.
LENSAR, Inc. (NASDAQ: LNSR) will announce its fourth quarter and full year 2020 financial results on March 10, 2021, before market open. A conference call and webcast will follow at 8:30 am ET that day to discuss the results and corporate updates. LENSAR specializes in advanced femtosecond laser systems for cataract treatments, incorporating proprietary technologies aimed at enhancing surgical efficiency and visual outcomes. Investors should note that forward-looking statements regarding the company's performance include inherent risks and uncertainties.
LENSAR, a global medical technology company specializing in advanced femtosecond laser solutions for cataracts, announced CEO Nick Curtis will present at two investor conferences. The BTIG Virtual MedTech Conference is scheduled for February 18, 2021, at 4:00 p.m. ET, followed by the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 3:40 p.m. ET. Investors can access live webcasts and replays on the Company’s website. LENSAR’s innovative laser system aims to enhance surgical outcomes through advanced imaging and precision.
LENSAR, Inc. (Nasdaq:LNSR) has expanded its Board of Directors to seven members with the appointments of Aimee S. Weisner and Elizabeth G. O’Farrell, effective February 1, 2021. Weisner will join the Compensation Committee, while O’Farrell will chair the Audit Committee. CEO Nick Curtis emphasized their expertise in global operations, finance, and regulatory environments, which will assist the company in achieving its strategic goals. The anticipated launch of the next-generation ALLY system is highlighted as a potential game-changer in cataract surgery.
LENSAR, Inc. (NASDAQ: LNSR), a leader in femtosecond laser surgical solutions for cataracts, announced CEO Nick Curtis will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference. The presentation will be available on-demand starting November 23, 2020, at 10 a.m. Eastern Time via the Company’s website. Curtis will also hold one-on-one meetings with investors on December 1 and 2, 2020. Investors can request meetings through Piper Sandler or by contacting Lee Roth.
About LENSAR: LENSAR specializes in advanced laser systems aimed at enhancing surgical outcomes for cataract treatment.
LENSAR, Inc. (NASDAQ: LNSR) has announced the acceptance of three posters and one paper for virtual presentations at the Annual Meeting of the American Academy of Ophthalmology (AAO), scheduled for November 13-15, 2020. The paper, titled 'Refractive Outcomes of a Light-Adjustable IOL in Cataract Patients With a History of RK,' will be presented by Dr. James D. Lehmann. The accepted posters include studies on the management of astigmatism during cataract surgery, with presentations by Dr. Seong-Jun Lee and Dr. Vasilios F. Diakonis, available on the AAO meeting portal starting November 11, 2020.
LENSAR, Inc. (NASDAQ: LNSR) reported third-quarter 2020 revenue of $7.1 million, down from $8.1 million in Q3 2019 due to pandemic-related disruptions. The total number of procedures sold was 25,078, almost flat year-over-year. Gross margin improved to $3.9 million (55% of revenue), up from $3.3 million (41% of revenue) in Q3 2019. Operating loss decreased to $(4.7) million from $(5.3) million. LENSAR remains on track to launch its ALLY system in 2022, with sufficient capital to support operations through the filing of its FDA application. Cash and cash equivalents stood at $42.7 million as of September 30, 2020.
LENSAR, Inc. (NASDAQ: LNSR) has officially completed its spin-off from PDL BioPharma, Inc. (NASDAQ: PDLI), with shares beginning regular trading on NASDAQ. The distribution grants PDL stockholders 0.075879 shares of LENSAR for each share of PDL held as of September 22, 2020. LENSAR specializes in femtosecond laser surgical solutions for cataract treatment, utilizing advanced technologies to enhance surgical outcomes.
FAQ
What is the current stock price of LENSAR (LNSR)?
What is the market cap of LENSAR (LNSR)?
What does LENSAR, Inc. specialize in?
What is the LENSAR Laser System?
What makes the LENSAR Laser System unique?
What is Augmented Reality™ in the context of LENSAR?
What is included in LENSAR's product portfolio?
What are the consumable components of the LENSAR Laser System?
What is the primary focus of LENSAR, Inc.?
How does LENSAR contribute to the surgical process?
How does LENSAR ensure the effectiveness of its technology?
What drives the success of LENSAR, Inc.?
